Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF)

Frost, Freddy
Young, Gregory R
Wright, Laura
Miah, Nahida
Smith, Darren L
Winstanley, Craig
Walshaw, Martin J
Fothergill, Joanne L
Nazareth, Dilip

January 2021

BackgroundThe objective of this study was to explore the clinical and microbiological outcomes assoc...

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

Plant, BJ
Downey, DG
Eustace, JA
Gunaratnam, C
Haworth, CS
Jones, AM
McKone, EF
Peckham, DG
Ketchell, RI
Bilton, D

November 2017

Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in pa...

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial

Tullis, D. Elizabeth
Burns, Jane L.
Retsch-Bogart, George Z.
Bresnik, Mark
Henig, Noreen R.
Lewis, Sandra A.
LiPuma, John J.

January 2014

AbstractBackgroundIndividuals with Burkholderia spp. infection have historically been excluded from ...

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

McCoy, Karen S.
Quittner, Alexandra L.
Oermann, Christopher M.
Gibson, Ronald L.
Retsch-Bogart, George Z.
Montgomery, A. Bruce

January 2008

Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with c...

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

Retsch-Bogart, George Z.
Quittner, Alexandra L.
Gibson, Ronald L.
Oermann, Christopher M.
McCoy, Karen S.
Montgomery, A. Bruce
Cooper, Peter J.

January 2009

We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosoli...

Is Aztreonam Lysine for Inhalation Effective in the Treatment of Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection?

Shevchenko, Christine

January 2014

OBJECTIVE: The objective of this selective EBM review is to determine whether or not aztreonam lysin...

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

Oermann, Christopher M.
Retsch-bogart, George Z.
Quittner, Alexandra L.
Gibson, Ronald L.
Mccoy, Karen S.
Montgomery, A. Bruce
Cooper, Peter J.

January 2010

Chronic airway infection with Pseudomonas aeruginosa (PA) causes morbidity and mortality in patients...

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis

Elizabeth Claire Elson
Joel Mermis
Deepika Polineni
Christopher M Oermann

April 2019

Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysre...

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

Wainwright, C.E.
Quittner, A.L.
Geller, D.E.
Nakamura, C.
Wooldridge, J.L.
Gibson, R.L.
Lewis, S.
Montgomery, A.B.

July 2011

AbstractBackgroundPrevious aztreonam for inhalation solution (AZLI) studies included patients with c...

Evidence for the efficacy of aztreonam for inhalation solution in the management of in patients with cystic fibrosis

Christine Hansen
Marianne Skov

February 2015

Chronic airway infection in cystic fibrosis (CF) is a main cause of the increased morbidity and mort...

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Tiddens, H.A.W.M.
De Boeck, K.
Clancy, J.P.
Fayon, M.
H.G.M., Arets
Bresnik, M.
Derchak, A.
Lewis, S.A.
Oermann, C.M.

January 2015

AbstractBackgroundConsensus guidelines recommend early treatment to eradicate newly acquired Pseudom...

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

12. Assael BM
Pressler T
Bilton D
Fayon M
Fischer R
Chiron R
La Rosa M
Knoop C
McElvaney N
Lewis SA
Bresnik M
Montgomery AB
Oermann CM
AZLI Active Comparator Study Group
VITALITI G
as corporate author

January 2013

Background: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

ASSAEL, BAROUKHMAURICE
Tacjana Pressler
Diana Bilton
Michael Fayon
Rainald Fischer
Raphael Chiron
Mario LaRosa
Christiane Knoop
Noel McElvaney
Sandra A. Lewis
Mark Bresnik
A. Bruce Montgomery
Christopher M. Oermann

January 2013

BACKGROUND: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...

Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary

September 2016

Inhaled antibiotic therapy in cystic fi-brosis (CF) may be used for multiple indications in patients...

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

Assael, Baroukh M.
Pressler, Tacjana
Bilton, Diana
Fayon, Michael
Fischer, Rainald
Chiron, Raphael
LaRosa, Mario
Knoop, Christiane
McElvaney, Noel
Lewis, Sandra A.
Bresnik, Mark
Montgomery, A. Bruce
Oermann, Christopher M.

March 2013

AbstractBackgroundOpen-label, parallel-group, international trial comparing aztreonam for inhalation...

The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF)

Frost, Freddy
Young, Gregory R
Wright, Laura
Miah, Nahida
Smith, Darren L
Winstanley, Craig
Walshaw, Martin J
Fothergill, Joanne L
Nazareth, Dilip

January 2021

BackgroundThe objective of this study was to explore the clinical and microbiological outcomes assoc...

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

Plant, BJ
Downey, DG
Eustace, JA
Gunaratnam, C
Haworth, CS
Jones, AM
McKone, EF
Peckham, DG
Ketchell, RI
Bilton, D

November 2017

Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in pa...

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial

Tullis, D. Elizabeth
Burns, Jane L.
Retsch-Bogart, George Z.
Bresnik, Mark
Henig, Noreen R.
Lewis, Sandra A.
LiPuma, John J.

January 2014

AbstractBackgroundIndividuals with Burkholderia spp. infection have historically been excluded from ...

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

McCoy, Karen S.
Quittner, Alexandra L.
Oermann, Christopher M.
Gibson, Ronald L.
Retsch-Bogart, George Z.
Montgomery, A. Bruce

January 2008

Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with c...

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

Retsch-Bogart, George Z.
Quittner, Alexandra L.
Gibson, Ronald L.
Oermann, Christopher M.
McCoy, Karen S.
Montgomery, A. Bruce
Cooper, Peter J.

January 2009

We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosoli...

Is Aztreonam Lysine for Inhalation Effective in the Treatment of Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection?

Shevchenko, Christine

January 2014

OBJECTIVE: The objective of this selective EBM review is to determine whether or not aztreonam lysin...

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

Oermann, Christopher M.
Retsch-bogart, George Z.
Quittner, Alexandra L.
Gibson, Ronald L.
Mccoy, Karen S.
Montgomery, A. Bruce
Cooper, Peter J.

January 2010

Chronic airway infection with Pseudomonas aeruginosa (PA) causes morbidity and mortality in patients...

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis

Elizabeth Claire Elson
Joel Mermis
Deepika Polineni
Christopher M Oermann

April 2019

Patients with cystic fibrosis (CF) develop pulmonary disease secondary to airway infection and dysre...

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

Wainwright, C.E.
Quittner, A.L.
Geller, D.E.
Nakamura, C.
Wooldridge, J.L.
Gibson, R.L.
Lewis, S.
Montgomery, A.B.

July 2011

AbstractBackgroundPrevious aztreonam for inhalation solution (AZLI) studies included patients with c...

Evidence for the efficacy of aztreonam for inhalation solution in the management of in patients with cystic fibrosis

Christine Hansen
Marianne Skov

February 2015

Chronic airway infection in cystic fibrosis (CF) is a main cause of the increased morbidity and mort...

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Tiddens, H.A.W.M.
De Boeck, K.
Clancy, J.P.
Fayon, M.
H.G.M., Arets
Bresnik, M.
Derchak, A.
Lewis, S.A.
Oermann, C.M.

January 2015

AbstractBackgroundConsensus guidelines recommend early treatment to eradicate newly acquired Pseudom...

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

12. Assael BM
Pressler T
Bilton D
Fayon M
Fischer R
Chiron R
La Rosa M
Knoop C
McElvaney N
Lewis SA
Bresnik M
Montgomery AB
Oermann CM
AZLI Active Comparator Study Group
VITALITI G
as corporate author

January 2013

Background: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

ASSAEL, BAROUKHMAURICE
Tacjana Pressler
Diana Bilton
Michael Fayon
Rainald Fischer
Raphael Chiron
Mario LaRosa
Christiane Knoop
Noel McElvaney
Sandra A. Lewis
Mark Bresnik
A. Bruce Montgomery
Christopher M. Oermann

January 2013

BACKGROUND: Open-label, parallel-group, international trial comparing aztreonam for inhalation solut...

Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary

September 2016

Inhaled antibiotic therapy in cystic fi-brosis (CF) may be used for multiple indications in patients...

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

Assael, Baroukh M.
Pressler, Tacjana
Bilton, Diana
Fayon, Michael
Fischer, Rainald
Chiron, Raphael
LaRosa, Mario
Knoop, Christiane
McElvaney, Noel
Lewis, Sandra A.
Bresnik, Mark
Montgomery, A. Bruce
Oermann, Christopher M.

March 2013

AbstractBackgroundOpen-label, parallel-group, international trial comparing aztreonam for inhalation...

The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF)

Frost, Freddy
Young, Gregory R
Wright, Laura
Miah, Nahida
Smith, Darren L
Winstanley, Craig
Walshaw, Martin J
Fothergill, Joanne L
Nazareth, Dilip

January 2021

BackgroundThe objective of this study was to explore the clinical and microbiological outcomes assoc...

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

Plant, BJ
Downey, DG
Eustace, JA
Gunaratnam, C
Haworth, CS
Jones, AM
McKone, EF
Peckham, DG
Ketchell, RI
Bilton, D

November 2017

Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in pa...

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial

Tullis, D. Elizabeth
Burns, Jane L.
Retsch-Bogart, George Z.
Bresnik, Mark
Henig, Noreen R.
Lewis, Sandra A.
LiPuma, John J.

January 2014

AbstractBackgroundIndividuals with Burkholderia spp. infection have historically been excluded from ...

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

Abstract

Extracted data

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

Abstract

Extracted data

Related items

Related items